GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (OTCPK:SHJBF) » Definitions » Total Assets

SHJBF (Shanghai Junshi Biosciences Co) Total Assets : $1,534.4 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shanghai Junshi Biosciences Co Total Assets?

Shanghai Junshi Biosciences Co's Total Assets for the quarter that ended in Sep. 2024 was $1,534.4 Mil.

Warning Sign:

If a company builds assets at 16.4% a year, faster than its revenue growth rate of 3.4% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Shanghai Junshi Biosciences Co's average Total Assets Growth Rate was 1.50% per year. During the past 3 years, the average Total Assets Growth Rate was -3.10% per year. During the past 5 years, the average Total Assets Growth Rate was 16.40% per year.

During the past 9 years, Shanghai Junshi Biosciences Co's highest 3-Year average Total Assets Growth Rate was 79.10%. The lowest was -3.10%. And the median was 47.90%.

Total Assets is connected with ROA %. Shanghai Junshi Biosciences Co's annualized ROA % for the quarter that ended in Sep. 2024 was -10.41%. Total Assets is also linked to Revenue through Asset Turnover. Shanghai Junshi Biosciences Co's Asset Turnover for the quarter that ended in Sep. 2024 was -0.07.


Shanghai Junshi Biosciences Co Total Assets Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Total Assets Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only 1,225.03 1,735.00 1,803.91 1,591.34 1,483.39

Shanghai Junshi Biosciences Co Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,591.34 1,669.72 1,517.34 1,534.43 1,483.39

Shanghai Junshi Biosciences Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Shanghai Junshi Biosciences Co's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=817.264+666.122
=1,483.4

Shanghai Junshi Biosciences Co's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (Q: Sep. 2024 )+Total Liabilities (Q: Sep. 2024 )
=887.499+646.929
=1,534.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Junshi Biosciences Co  (OTCPK:SHJBF) Total Assets Explanation

Total Assets is connected with ROA %.

Shanghai Junshi Biosciences Co's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-158.892/( (1517.344+1534.428)/ 2 )
=-158.892/1525.886
=-10.41 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Shanghai Junshi Biosciences Co's Asset Turnover for the quarter that ended in Sep. 2024 is

Asset Turnover
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-111.088/( (1517.344+1534.428)/ 2 )
=-111.088/1525.886
=-0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Shanghai Junshi Biosciences Co Total Assets Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi Biosciences Co Ltd is a China-based biotechnology companyy with all-round capabilities in innovative drug discovery and development, clinical research on a global scale, large-scale production capacity to commercialization on the full industry chain. Aiming to develop first-in-class or bestin-class drugs by way of original innovation and co-development. Companies operations are located in the PRC and the USA.